Public consultation on applications to be considered by the MSAC PASC (April 2024)

Closed 15 Mar 2024

Opened 2 Feb 2024


Consultation is now open for applications that are anticipated to be considered by the PICO Advisory Sub-Committee (PASC) of the Medical Services Advisory Committee (MSAC) on 18-19 April 2024.

PASC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.   

It is anticipated that the below-mentioned applications will proceed to PASC in April 2023. Consultation input must be received by no later than Friday, 15 March 2024 for it to be considered by PASC. A consultation survey form is available on the relevant application webpage.

Further information on MSAC’s consultation process is also available on the MSAC website.

Applications scheduled to be considered:

1751 – Valoctocogene roxaparvovec gene therapy for haemophilia A

1766 – Genetic testing to detect AKT-pathway alterations in patients with hormone receptor-positive, HER2-negative advanced breast cancer, to determine eligibility for PBS subsidised capivasertib treatment

1767 – Immunohistochemistry testing for Claudin 18 expression in patients with gastric or gastro-oesophageal junction cancers, to determine eligibility for PBS subsidised zolbetuximab treatment

1769 – Human leukocyte antigen testing for sensitivity to carbamazepine in patients with epilepsy

1770 – Valve-in-valve transcatheter aortic valve implantation using a balloon-expanding transcatheter heart valve system

1772 – Single chamber leadless pacing with atrio-ventricular synchronous pacing in patients with bradycardia

1773 – Autologous chondrocyte implantation for symptomatic articular cartilage defects greater than 2cm2 of the knee

1774 – Newborn bloodspot screening for glycogen storage disease, Type II (Pompe disease)

1775 – Newborn bloodspot screening for mucopolysaccharidosis, Type 1 (MPS I)

1776 – Newborn bloodspot screening for mucopolysaccharidosis, Type II (MPS II)

What happens next

Once the consultation closes, all submissions received will be compiled and summarised in the draft PICO Confirmation that sets out the proposed parameters upon which the assessment is based.

The PASC meets to discuss the draft PICO Confirmation and the consultation comments that have been received.

Once the PICO Confirmation is ratified by the PASC, the PICO Confirmation is published on the relevant application webpage on the MSAC website.


  • Anyone from any background


  • All